International Journal For Multidisciplinary Research

E-ISSN: 2582-2160     Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 7, Issue 4 (July-August 2025) Submit your research before last 3 days of August to publish your research paper in the issue of July-August.

Exploring Triphala's Therapeutic Potential: Targeting AD Pathology Proteins BACE1, GSK3β, and MMP9 through InSilico Approaches

Author(s) Mr. Somdeb Bhattacharya, Dr. Sujoy Ghosh
Country India
Abstract Alzheimer's disease (AD) and associated dementia have emerged as prominent
global health concerns over recent decades. Characterized by complex genetic,
epigenetic, and metabolomic alterations, AD remains incurable. Extensive
exploration into the genetic landscape of AD pathology has led to the
identification of several biomarkers strongly implicated in the disease, including
GSK3ß, BACE1, and MMP9, alongside the hallmark APP and Tau-related
neurofibrillary tangle formation. While certain commercially available drugs
such as memantine and donepezil are utilized in AD treatment, their efficacy is
subject to debate, with notable side effects. Consequently, attention has turned to
Ayurvedic herbal components, frequently consumed in India, renowned for their
diverse health benefits and comparatively lower adverse effects. In this
investigation, Triphala, a composite formulation comprising extracts from
Emblica officinalis, Terminalia chebula, and Terminalia bellerica, was selected
for the study. Through identification of the bioactive constituents of these plant
extracts, molecular docking analyses were conducted with GSK3ß, BACE1, and
MMP9 proteins. Findings indicate that the bioactive constituents of Triphala
exhibit enhanced interactions with these target proteins, suggesting a potential
improvement in AD pathology through Triphala consumption. However, it is
imperative to underscore that further molecular experimentation in laboratory
settings is essential to validate these initial findings conclusively. Looking ahead,
the composition of Triphala holds promise as a prospective therapeutic agent for
the treatment of AD-associated dementia.
Keywords Alzheimer’s Disease (AD), Triphala, Biomarkers, GSK3ß, BACE1, MMP9, Emblica officinalis, Terminalia chebula, Terminalia bellerica, APP, moleculer docking
Field Biology > Genetics / Molecular
Published In Volume 7, Issue 4, July-August 2025
Published On 2025-08-04

Share this